Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric multiple sclerosis trial of ofatumumab and siponimod versus fingolimod with open-label extension
2024-511686-11-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ofatumumab arm, Siponimod arm and Fingolimod arm (3 arms). Primary endpoint: Annualized relapse rate of confirmed relapses. Planned start Oct 2021; status: authorised.
02
Drugs
ofatumumabsiponimodfingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-511686-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511686-11-00.